This proposal aims to develop software that will speed the optimization of lead candidates for new drugs. At present, high throughput screening enables pharmaceutical companies to discover rapidly and in significant number lead compounds for new medications. However, years of research and development are required to optimize these leads as suitable therapeutics. Our software will expedite this process by simulating the reactions of combinatorial chemistry that are used to optimize lead compounds and then using scoring functions to identify the most promising of the derivatives that are generated.

Proposed Commercial Applications

The software created in this research will accelerate the optimization of lead compounds for drug development by exploiting virtual combinatorial chemistry. The time savings in the development of any single drug will translate into millions of dollars. The market for this product includes anyone involved in drug discovery and development, ranging from established pharmaceutical companies to startup biotech concerns.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43GM060865-01
Application #
6073566
Study Section
Special Emphasis Panel (ZRG1-SSS-9 (23))
Program Officer
Schwab, John M
Project Start
2000-03-01
Project End
2000-08-31
Budget Start
2000-03-01
Budget End
2000-08-31
Support Year
1
Fiscal Year
2000
Total Cost
$79,550
Indirect Cost
Name
Drug Design Methodologies, LLC
Department
Type
DUNS #
City
St. Louis
State
MO
Country
United States
Zip Code
63108